Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
The International Journal of Neuropsychopharmacology April 7, 2020 Michel Nijs, Ewa Wajs, Leah Aluisio et al. 21 citations
BACKGROUND: Esketamine nasal spray was recently approved for treatment-resistant depression. The current analysis evaluated the impact of symptom-based treatment frequency changes during esketamine treatment on clinical outcomes. METHODS: This is a post-hoc analysis of an open-label, long-term (up to 1 year) study of esketamine in patients with treatment-resistant depression (SUSTAIN 2). During...